466 related articles for article (PubMed ID: 6986409)
1. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Samojlik E; Veldhuis JD; Wells SA; Santen RJ
J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
[TBL] [Abstract][Full Text] [Related]
2. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Samojlik E; Santen RJ; Kirschner MA; Ertel NH
Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
[TBL] [Abstract][Full Text] [Related]
3. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H
Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
[TBL] [Abstract][Full Text] [Related]
4. How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
Worgul TJ; Santen RJ; Samojlik E; Wells SA
J Clin Endocrinol Metab; 1982 Jan; 54(1):22-6. PubMed ID: 6459336
[TBL] [Abstract][Full Text] [Related]
5. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
Samojlik E; Santen RJ
J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
[TBL] [Abstract][Full Text] [Related]
7. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.
Morris KT; Toth-Fejel S; Schmidt J; Fletcher WS; Pommier RF
Surgery; 2001 Dec; 130(6):947-53. PubMed ID: 11742322
[TBL] [Abstract][Full Text] [Related]
8. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison.
Castelo-Branco C; Martínez de Osaba MJ; Fortuny A; Iglesias X; González-Merlo J
J Reprod Med; 1995 Aug; 40(8):556-60. PubMed ID: 7473451
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.
Santen RJ; Worgul TJ; Samojlik E; Interrante A; Boucher AE; Lipton A; Harvey HA; White DS; Smart E; Cox C; Wells SA
N Engl J Med; 1981 Sep; 305(10):545-51. PubMed ID: 7019703
[TBL] [Abstract][Full Text] [Related]
10. Is aminoglutethimide an alternative to adrenalectomy for metastatic carcinoma of the breast?
Sterns EE; Bird CE; Mackie KW
Can J Surg; 1982 Nov; 25(6):695-7. PubMed ID: 7139430
[TBL] [Abstract][Full Text] [Related]
11. The endocrine transition around menopause--a five years prospective study with profiles of gonadotropines, estrogens, androgens and SHBG among healthy women.
Overlie I; Moen MH; Morkrid L; Skjaeraasen JS; Holte A
Acta Obstet Gynecol Scand; 1999 Aug; 78(7):642-7. PubMed ID: 10422913
[TBL] [Abstract][Full Text] [Related]
12. Cancer of the breast. Endocrine and hormonal therapy.
Kardinal CG; Donegan WL
Major Probl Clin Surg; 1979; 5():361-404. PubMed ID: 379452
[TBL] [Abstract][Full Text] [Related]
13. [The use of aminoglutethimide in the treatment of metastatic breast cancer].
Bellora MG; Ciancio A; Ferrero A; Bergamino T; Zola P; Sismondi P
Minerva Ginecol; 1991 Dec; 43(12):589-93. PubMed ID: 1819778
[TBL] [Abstract][Full Text] [Related]
14. Plasma estrone-sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma.
Samojlik E; Santen RJ; Worgul TJ
Steroids; 1982 May; 39(5):497-507. PubMed ID: 6293125
[TBL] [Abstract][Full Text] [Related]
15. Ovarian and adrenal contributions to peripheral steroid levels in postmenopausal women.
Maroulis GB; Abraham GE
Obstet Gynecol; 1976 Aug; 48(2):150-4. PubMed ID: 133306
[TBL] [Abstract][Full Text] [Related]
16. Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy.
Samojlik E; Santen RJ; Worgul TJ
Clin Endocrinol (Oxf); 1984 Jan; 20(1):43-51. PubMed ID: 6692582
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
Aggarwal R; Weinberg V; Small EJ; Oh W; Rushakoff R; Ryan CJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E71-6. PubMed ID: 19815485
[TBL] [Abstract][Full Text] [Related]
18. Influence of conjugated oestrogens on circulating oestradiol, oestrone, LH, FSH and prolactin levels in postmenopausal women.
Luisi M; Franchi F; Argenio GF; Barletta D; Romano MR; Bernini GP; Gasperi M; Sgrilli R
Int J Tissue React; 1981 Jun; 3(2):77-81. PubMed ID: 6799393
[TBL] [Abstract][Full Text] [Related]
19. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
